KathleenNMooreMD

Obstetrics & Gynecology • Oklahoma City, OK

Gynecologic Oncology, Hospice & Palliative Medicine

Assistant Professor, Obstetrics & Gynecology, University of Oklahoma College of Medicine

Join to view full profile

Are you Dr. Moore?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 76 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
825 NE 10th St
Oupb5200
Oklahoma City, OK 73104
Phone+1 405-271-7770

Summary

Dr. Kathleen Moore, MD is an obstetrician/gynecologist in Oklahoma City, Oklahoma. She is currently licensed to practice medicine in Oklahoma and Pennsylvania. She is affiliated with OU Health, SSM Health St. Anthony Hospital - Oklahoma City, and INTEGRIS Baptist Medical Center.

Education & Training

UPMC Medical EducationResidency, Obstetrics and Gynecology, 2000 - 2004
University of Washington School of MedicineClass of 2000

Certifications & Licensure

OK State Medical License 2004 - 2025
PA State Medical License 2001 - 2004
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Clinical Trials

Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers Start of enrollment: 2008 Jul 01
Completed
Phase 1
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Start of enrollment: 2011 Jun 06
Completed
Phase 2
Safety Study of X-82 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Feb 01
Completed
Phase 1
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer Start of enrollment: 2012 Feb 01
Terminated
Phase 1, Phase 2
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors Start of enrollment: 2012 Jun 28
Completed
Phase 1
Randomized Phase II Study of Intravenous 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine® NSC #663249) Cisplatin-Radiochemotherapy Versus Intravenous Cisplatin-Radiochemotherapy in Women Diagnosed With Stage IB-IVA Cervical Cancer and S Start of enrollment: 2013 Apr 01
Study of Safety & Biological Activity of IP IMNN-001 (Also Known as GEN-1) With Neoadjuvant Chemo in Ovarian Cancer Start of enrollment: 2015 Sep 01
Completed
Phase 1
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer Start of enrollment: 2016 Oct 01
Terminated
Phase 1
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer Start of enrollment: 2016 Dec 01
Completed
Phase 1
Study of AGEN2034 in Advanced Tumors and Cervical Cancer Start of enrollment: 2017 Apr 11
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.
Stéphanie Gaillard, Christina Lacchetti, Deborah K Armstrong, William A Cliby, Mitchell I Edelson
Journal of Clinical Oncology. 2025-01-22
Assay for the quantification of abemaciclib, its metabolites, and olaparib in human plasma by liquid chromatography-tandem mass spectrometry.
Kasey L Hill, Nicole L Abbott, Joo Young Na, Michelle Rudek, Kathleen Moore
Journal of Pharmaceutical and Biomedical Analysis. 2025-01-15
A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors.
Chadi Hage Chehade, Georges Gebrael, Nicolas Sayegh, Zeynep Irem Ozay, Arshit Narang
CA. 2025-01-10

Press Mentions

Five OU Researchers Among Top 1% Most Highly Cited WorldwideJanuary 13th, 2025
After Clovis Pulls Third-Line Indication, What Is Rucaparib’s Future for Ovarian Cancer?July 27th, 2022
VBL Therapeutics to Host in-Person Key Opinion Leader Seminar on Ovarian CancerMarch 31st, 2022
Join now to see all